Roles of FGF signals in heart development, health, and disease

Frontiers in Cell and Developmental Biology

Volumn 4, Issue OCT, 2016, Pages

  Itoh, Nobuyuki ^a   Ohta, Hiroya ^b   Nakayama, Yoshiaki ^b   Konishi, Morichika ^b  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KOBE PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Biomarker; Development; Differentiation; Disease; FGF; Heart

Indexed keywords

EID: 85013960868     PISSN: None     EISSN: 2296634X     Source Type: Journal    
DOI: 10.3389/fcell.2016.00110     Document Type: Review

References (94)

1. Ables, G. P., Ouattara, A., Hampton, T. G., Cooke, D., Perodin, F., Augie, I., et al. (2015). Dietary methionine restriction in mice elicits an adaptive cardiovascular response to hyperhomocysteinemia. Sci. Rep. 5:8886. doi: 10.1038/srep08886
2. Abu-Issa, R., Smyth, G., Smoak, I., Yamamura, K., and Meyers, E. N. (2002). Fgf8 is required for pharyngeal arch and cardiovascular development in the mouse. Development 129, 4613-4625
3. Andersen, I. A., Huntley, B. K., Sandberg, S. S., Heublein, D. M., and Burnett, J. C. Jr. (2016). Elevation of circulating but not myocardial FGF23 in human acute decompensated heart failure. Nephrol. Dial. Transplant. 31, 767-772. doi: 10.1093/ndt/gfv398
4. Brewer, J. R., Mazot, P., and Soriano, P. (2016). Genetic insights into the mechanisms of Fgf signaling. Genes Dev. 30, 751-771. doi: 10.1101/gad.277137.115
5. Carter, E. P., Fearon, A. E., and Grose, R. P. (2015). Careless talk costs lives: fibroblast growth factor receptor signalling and the consequences of pathway malfunction. Trends Cell Biol. 25, 221-233. doi: 10.1016/j.tcb.2014.11.003
6. Chan, S. S., Li, H. J., Hsueh, Y. C., Lee, D. S., Chen, J. H., Hwang, S. M., et al. (2010). Fibroblast growth factor-10 promotes cardiomyocyte differentiation from embryonic and induced pluripotent stem cells. PLoS ONE 5:e14414. doi: 10.1371/journal.pone.0014414
7. Colvin, J. S., White, A. C., Pratt, S. J., and Ornitz, D. M. (2001). Lung hypoplasia and neonatal death in Fgf9-null mice identify this gene as an essential regulator of lung mesenchyme. Development 128, 2095-2106
8. Degirolamo, C., Sabbà, C., and Moschetta, A. (2016). Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23. Nat. Rev. Drug Discov. 15, 51-69. doi: 10.1038/nrd.2015.9
9. Di Lisa, F., and Itoh, N. (2015). Cardiac Fgf21 synthesis and release: an autocrine loop for boosting up antioxidant defenses in failing hearts. Cardiovasc. Res. 106, 1-3. doi: 10.1093/cvr/cvv050
10. Domouzoglou, E. M., Naka, K. K., Vlahos, A. P., Papafaklis, M. I., Michalis, L. K., Tsatsoulis, A., et al. (2015). Fibroblast growth factors in cardiovascular disease: the emerging role of FGF21. Am. J. Physiol. Heart Circ. Physiol. 309, H1029-H1038. doi: 10.1152/ajpheart.00527.2015
11. Doroudgar, S., and Glembotski, C. C. (2011). The cardiokine story unfolds: ischemic stress-induced protein secretion in the heart. Trends Mol. Med. 17, 207-214. doi: 10.1016/j.molmed.2010.12.003
12. Erben, R. G. (2016). Update on FGF23 and Klotho signaling. Mol. Cell. Endocrinol. 432, 56-65. doi: 10.1016/j.mce.2016.05.008
13. Falcini, F., Rigante, D., Masi, L., Covino, M., Franceschelli, F., Leoncini, G., et al. (2013). Fibroblast growth factor 23 (FGF23) gene polymorphism in children with Kawasaki syndrome (KS) and susceptibility to cardiac abnormalities. Ital. J. Pediatr. 39:69. doi: 10.1186/1824-7288-39-69
14. Faul, C. (2012). Fibroblast growth factor 23 and the heart. Curr. Opin. Nephrol. Hypertens. 21, 369-375. doi: 10.1097/MNH.0b013e32835422c4
15. Faul, C., Amaral, A. P., Oskouei, B., Hu, M. C., Sloan, A., Isakova, T., et al. (2011). FGF23 induces left ventricular hypertrophy. J. Clin. Invest. 121, 4393-4408. doi: 10.1172/JCI46122
16. Fon Tacer, K., Bookout, A. L., Ding, X., Kurosu, H., John, G. B., Wang, L., et al. (2010). Research resource: comprehensive expression atlas of the fibroblast growth factor system in adult mouse. Mol. Endocrinol. 24, 2050-2064. doi: 10.1210/me.2010-0142
17. Grabner, A., Amaral, A. P., Schramm, K., Singh, S., Sloan, A., Yanucil, C., et al. (2015). Activation of cardiac fibroblast growth factor receptor 4 causes left ventricular hypertrophy. Cell Metab. 22, 1020-1032. doi: 10.1016/j.cmet.2015.09.002
18. Hao, Y., Zhou, J., Zhou, M., Ma, X., Lu, Z., Gao, M., et al. (2013). Serum levels of fibroblast growth factor 19 are inversely associated with coronary artery disease in chinese individuals. PLoS ONE 8:e72345. doi: 10.1371/journal.pone.0072345
19. Hotta, Y., Sasaki, S., Konishi, M., Kinoshita, H., Kuwahara, K., Nakao, K., et al. (2008). Fgf16 is required for cardiomyocyte proliferation in the mouse embryonic heart. Dev. Dyn. 237, 2947-2954. doi: 10.1002/dvdy.21726
20. House, S. L., House, B. E., Glascock, B., Kimball, T., Nusayr, E., Schultz, J. E. J., et al. (2010). Fibroblast growth factor 2 mediates isoproterenol-induced cardiac hypertrophy through activation of the extracellular regulated kinase. Mol. Cell. Pharmacol. 2, 143-154. doi: 10.4255/mcpharmacol.10.20
21. House, S. L., Wang, J., Castro, A. M., Weinheimer, C., Kovacs, A., and Ornitz, D. M. (2015). Fibroblast growth factor 2 is an essential cardioprotective factor in a closed-chest model of cardiac ischemia-reperfusion injury. Physiol. Rep. 3:e12278. doi: 10.14814/phy2.12278
22. Ilagan, R., Abu-Issa, R., Brown, D., Yang, Y. P., Jiao, K., Schwartz, R. J., et al. (2006). Fgf8 is required for anterior heart field development. Development 133, 2435-2445. doi: 10.1242/dev.02408
23. Imazu, M., Takahama, H., Asanuma, H., Funada, A., Sugano, Y., Ohara, T., et al. (2014). Pathophysiological impact of serum fibroblast growth factor 23 in patients with nonischemic cardiac disease and early chronic kidney disease. Am. J. Physiol. Heart Circ. Physiol. 307, H1504-H1511. doi: 10.1152/ajpheart.00331.2014
24. Ito, S., Fujimori, T., Furuya, A., Satoh, J., Nabeshima, Y., and Nabeshima, Y. (2005). Impaired negative feedback suppression of bile acid synthesis in mice lacking betaKlotho. J. Clin. Invest. 115, 2202-2208. doi: 10.1172/JCI23076
25. Itoh, N. (2016). FGF10: A multifunctional mesenchymal-epithelial signaling growth factor in development, health, and disease. Cytokine Growth Factor Rev. 28, 63-69. doi: 10.1016/j.cytogfr.2015.10.001
26. Itoh, N., Nakayama, Y., and Konishi, M. (2016). Roles of FGFs as paracrine or endocrine signals in liver development, health, and disease. Front. Cell Dev. Biol. 4:30. doi: 10.3389/fcell.2016.00030
27. Itoh, N., and Ohta, H. (2013). Pathophysiological roles of FGF signaling in the heart. Front Physiol. 4:247. doi: 10.3389/fphys.2013.00247
28. Itoh, N., Ohta, H., and Konishi, M. (2015). Endocrine FGFs: evolution, physiology, pathophysiology, and pharmacotherapy. Front. Endocrinol. 6:154. doi: 10.3389/fendo.2015.00154
29. Jimbo, R., and Shimosawa, T. (2014). Cardiovascular risk factors and chronic kidney disease-FGF23: a key molecule in the cardiovascular disease. Int. J. Hypertens. 2014:381082. doi: 10.1155/2014/381082
30. Joki, Y., Ohashi, K., Yuasa, D., Shibata, R., Ito, M., Matsuo, K., et al. (2015). FGF21 attenuates pathological myocardial remodeling following myocardial infarction through the adiponectin-dependent mechanism. Biochem. Biophys. Res. Commun. 459, 124-130. doi: 10.1016/j.bbrc.2015.02.081
31. Karatolios, K., Moosdorf, R., Maisch, B., and Pankuweit, S. (2012). Cytokines in pericardial effusion of patients with inflammatory pericardial disease. Mediators Inflamm. 2012:382082. doi: 10.1155/2012/382082
32. Kawai, T., Takahashi, T., Esaki, M., Ushikoshi, H., Nagano, S., Fujiwara, H., et al. (2004). Efficient cardiomyogenic differentiation of embryonic stem cell by fibroblast growth factor 2 and bone morphogenetic protein 2. Circ. J. 68, 691-702. doi: 10.1253/circj.68.691
33. Kaye, D. M., Kelly, R. A., and Smith, T. W. (1996). Cytokines and cardiac hypertrophy: roles of angiotensin II and basic fibroblast growth factor. Clin. Exp. Pharmacol. Physiol. 23, S136-S141
34. Kharitonenkov, A., and DiMarchi, R. (2015). FGF21 revolutions: recent advances illuminating FGF21 biology and medicinal properties. Trends Endocrinol. Metab. 26, 608-617. doi: 10.1016/j.tem.2015.09.007
35. Kim, W. J., Kim, S. S., Lee, H. C., Song, S. H., Bae, M. J., Yi, Y. S., et al. (2015). Association between serum fibroblast growth factor 21 and coronary artery disease in patients with type 2 diabetes. J. Korean Med. Sci. 30, 586-590. doi: 10.3346/jkms.2015.30.5.586
36. Koller, L., Kleber, M. E., Brandenburg, V. M., Goliasch, G., Richter, B., Sulzgruber, P., et al. (2015). Fibroblast growth factor 23 is an independent and specific predictor of mortality in patients with heart failure and reduced ejection fraction. Circ. Heart Fail. 8, 1059-1067. doi: 10.1161/circheartfailure.115.002341
37. Korf-Klingebiel, M., Kempf, T., Schlüter, K. D., Willenbockel, C., Brod, T., Heineke, J., et al. (2011). Conditional transgenic expression of fibroblast growth factor 9 in the adult mouse heart reduces heart failure mortality after myocardial infarction. Circulation 12, 504-514. doi: 10.1161/CIRCULATIONAHA.110.989665
38. Laurell, T., Nilsson, D., Hofmeister, W., Lindstrand, A., Ahituv, N., Vandermeer, J., et al. (2014). Identification of three novel FGF16 mutations in X-linked recessive fusion of the fourth and fifth metacarpals and possible correlation with heart disease. Mol. Genet. Genomic Med. 2, 402-411. doi: 10.1002/mgg3.81
39. Lavine, K. J., Yu, K., White, A. C., Zhang, X., Smith, C., Partanen, J., et al. (2005). Endocardial and epicardial derived FGF signals regulate myocardial proliferation and differentiation in vivo. Dev. Cell 8, 85-95. doi: 10.1016/j.devcel.2004.12.002
40. Lee, Y., Lim, S., Hong, E. S., Kim, J. H., Moon, M. K., Chun, E. J., et al. (2014). Serum FGF21 concentration is associated with hypertriglyceridaemia, hyperinsulinaemia and pericardial fat accumulation, independently of obesity, but not with current coronary artery status. Clin. Endocrinol. 80, 57-64. doi: 10.1111/cen.12134
41. Leifheit-Nestler, M., Große Siemer, R., Flasbart, K., Richter, B., Kirchhoff, F., Ziegler, W. H., et al. (2016). Induction of cardiac FGF23/FGFR4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease. Nephrol. Dial. Transplant. 31, 1088-1099. doi: 10.1093/ndt/gfv421
42. Lin, Z., Wu, Z., Yin, X., Liu, Y., Yan, X., Lin, S., et al. (2010). Serum levels of FGF-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profile. PLoS ONE 5:e15534. doi: 10.1371/journal.pone.0015534
43. Liu, M., Chen, H., Jiang, J., Zhang, Z., Wang, C., Zhang, N., et al. (2016). Stem cells and diabetic cardiomyopathy: from pathology to therapy. Heart Fail. Rev. [Epub ahead of print]. doi: 10.1007/s10741-016-9565-4
44. Liu, S. Q., Roberts, D., Kharitonenkov, A., Zhang, B., Hanson, S. M., Li, Y. C., et al. (2013). Endocrine protection of ischemic myocardium by FGF21 from the liver and adipose tissue. Sci. Rep. 3:2767. doi: 10.1038/srep02767
45. Liu, Y., Liu, Y., Liu, X., Chen, J., Zhang, K., Huang, F., et al. (2015). Apocynin attenuates cardiac injury in type 4 cardiorenal syndrome via suppressing cardiac fibroblast growth factor-2 with oxidative stress inhibition. J. Am. Heart Assoc. 4:e001598. doi: 10.1161/JAHA.114.001598
46. Lu, S. Y., Jin, Y., Li, X., Sheppard, P., Bock, M. E., Sheikh, F., et al. (2010). Embryonic survival and severity of cardiac and craniofacial defects are affected by genetic background in fibroblast growth factor-16 null mice. DNA Cell Biol. 9, 407-415. doi: 10.1089/dna.2010.1024
47. Lu, S. Y., Sheikh, F., Sheppard, P. C., Fresnoza, A., Duckworth, M. L., Detillieux, K. A., et al. (2008). FGF-16 is required for embryonic heart development. Biochem. Biophys. Res. Commun. 373, 270-274. doi: 10.1016/j.bbrc.2008.06.029
48. Lutsey, P. L., Alonso, A., Selvin, E., Pankow, J. S., Michos, E. D., Agarwal, S. K., et al. (2014). Fibroblast growth factor-23 and incident coronary heart disease, heart failure, and cardiovascular mortality: the atherosclerosis risk in communities study. J. Am. Heart Assoc. 3:e000936. doi: 10.1161/JAHA.114.000936
49. Masi, L., Franceschelli, F., Leoncini, G., Gozzini, A., Rigante, D., La Torre, F., et al. (2013). Can fibroblast growth factor (FGF)-23 circulating levels suggest coronary artery abnormalities in children with Kawasaki disease? Clin. Exp. Rheumatol. 31, 149-153
50. Mathew, J. S., Sachs, M. C., Katz, R., Patton, K. K., Heckbert, S. R., Hoofnagle, A. N., et al. (2014). Fibroblast growth factor-23 and incident atrial fibrillation: the Multi-Ethnic Study of Atherosclerosis (MESA) and the Cardiovascular Health Study (CHS). Circulation 130, 298-307. doi: 10.1161/CIRCULATIONAHA.113.005499
51. Matsumoto, E., Sasaki, S., Kinoshita, H., Kito, T., Ohta, H., Konishi, M., et al. (2013). Angiotensin II-induced cardiac hypertrophy and fibrosis are promoted in mice lacking Fgf16. Genes Cells 18, 544-553. doi: 10.1111/gtc.12055
52. Meganathan, K., Sotiriadou, I., Natarajan, K., Hescheler, J., and Sachinidis, A. (2015). Signaling molecules, transcription growth factors and other regulators revealed from in-vivo and in-vitro models for the regulation of cardiac development. Int. J. Cardiol. 183, 117-128. doi: 10.1016/j.ijcard.2015.01.049
53. Miquero, L., and Kelly, R. G. (2013). Organogenesis of the vertebrate heart. WIREs Dev. Biol. 2, 17-29. doi: 10.1002/wdev.68
54. Nies, V. J., Sancar, G., Liu, W., van Zutphen, T., Struik, D., Yu, R. T., et al. (2016). Fibroblast growth factor signaling in metabolic regulation. Front. Endocrinol. 6:193. doi: 10.3389/fendo.2015.00193
55. Ornitz, D. M., and Itoh, N. (2015). The fibroblast growth factor signaling pathway. WIREs Dev. Biol. 4, 215-266. doi: 10.1002/wdev.176
56. Ornitz, D. M., and Marie, P. J. (2015). Fibroblast growth factor signaling in skeletal development and disease. Genes Dev. 29, 1463-1486. doi: 10.1101/gad.266551.115
57. Pellieux, C., Foletti, A., Peduto, G., Aubert, J. F., Nussberger, J., Beermann, F., et al. (2001). Dilated cardiomyopathy and impaired cardiac hypertrophic response to angiotensin II in mice lacking FGF-2. J. Clin. Invest. 108, 1843-1851. doi: 10.1172/JCI13627
58. Planavila, A., Redondo-Angulo, I., Ribas, F., Garrabou, G., Casademont, J., Giralt, M., et al. (2015b). Fibroblast growth factor 21 protects the heart from oxidative stress. Cardiovasc. Res. 106, 19-31. doi: 10.1093/cvr/cvu263
59. Planavila, A., Redondo-Angulo, I., and Villarroya, F. (2015a). FGF21 and cardiac physiopathology. Front. Endocrinol. 6:133. doi: 10.3389/fendo.2015.00133
60. Planavila, A., Redondo, I., Hondares, E., Vinciguerra, M., Munts, C., Iglesias, R., et al. (2013). Fibroblast growth factor 21 protects against cardiac hypertrophy in mice. Nat. Commun. 4, 2019. doi: 10.1038/ncomms3019
61. Richter, M., Lautze, H. J., Walther, T., Braun, T., Kostin, S., and Kubin, T. (2015). The failing heart is a major source of circulating FGF23 via oncostatin M receptor activation. J. Heart Lung Transplant. 34, 1211-1214. doi: 10.1016/j.healun.2015.06.007
62. Rochais, F., Sturny, R., Chao, C. M., Mesbah, K., Bennett, M., Mohun, T. J., et al. (2014). FGF10 promotes regional foetal cardiomyocyte proliferation and adult cardiomyocyte cell-cycle re-entry. Cardiovasc. Res. 104, 432-442. doi: 10.1093/cvr/cvu232
63. Rubin, N., Darehzereshki, A., Bellusci, S., Kaartinen, V., and Ling Lien, C. (2013). FGF10 signaling enhances epicardial cell expansion during neonatal mouse heart repair. J. Cardiovasc. Dis. Diagn. 1:101. doi: 10.4172/2329-9517.1000101
64. Sadahiro, T., Yamanaka, S., and Ieda, M. (2015). Direct cardiac reprogramming: progress and challenges in basic biology and clinical applications. Circ. Res. 116, 1378-1391. doi: 10.1161/CIRCRESAHA.116.305374
65. Sekine, K., Ohuchi, H., Fujiwara, M., Yamasaki, M., Yoshizawa, T., Sato, T., et al. (1999). Fgf10 is essential for limb and lung formation. Nat. Genet. 21, 138-141. doi: 10.1038/5096
66. Shen, Y., Ma, X., Zhou, J., Pan, X., Hao, Y., Zhou, M., et al. (2013). Additive relationship between serum fibroblast growth factor 21 level and coronary artery disease. Cardiovasc. Diabetol. 12:124. doi: 10.1186/1475-2840-12-124
67. Singla, D. K., Singla, R. D., Abdelli, L. S., and Glass, C. (2015). Fibroblast growth factor-9 enhances M2 macrophage differentiation and attenuates adverse cardiac remodeling in the infarcted diabetic heart. PLoS ONE 10:e0120739. doi: 10.1371/journal.pone.0120739
68. Sun, X., Meyers, E. N., Lewandoski, M., and Martin, G. R. (1999). Targeted disruption of Fgf8 causes failure of cell migration in the gastrulating mouse embryo. Genes Dev. 13, 1834-1846. doi: 10.1101/gad.13.14.1834
69. Svystonyuk, D. A., Ngu, J. M., Mewhort, H. E., Lipon, B. D., Teng, G., Guzzardi, D. G., et al. (2015). Fibroblast growth factor-2 regulates human cardiac myofibroblast-mediated extracellular matrix remodeling. J. Transl. Med. 13, 147. doi: 10.1186/s12967-015-0510-4
70. Takahashi, K., and Yamanaka, S. (2015). A developmental framework for induced pluripotency. Development 142, 3274-3285. doi: 10.1242/dev.114249
71. Terzic, A., and Behfar, A. (2016). Stem cell therapy for heart failure: ensuring regenerative proficiency. Trends Cardiovasc. Med. 26, 395-404. doi: 10.1016/j.tcm.2016.01.003
72. Tuñón, J., Fernández-Fernández, B., Carda, R., Pello, A. M., Cristóbal, C., Tarín, N., et al. (2016). Circulating fibroblast growth factor-23 plasma levels predict adverse cardiovascular outcomes in coronary artery disease patients with diabetes mellitus. Diabetes Metab. Res. Rev. [Epub ahead of print]. doi: 10.1002/dmrr.2787
73. Turner, C. A., Eren-Koçak, E., Inui, E. G., Watson, S. J., and Akil, H. (2016). Dysregulated fibroblast growth factor (FGF) signaling in neurological and psychiatric disorders. Semin. Cell Dev. Biol. 53, 136-143. doi: 10.1016/j.semcdb.2015.10.003
74. Urness, L. D., Bleyl, S. B., Wright, T. J., Moon, A. M., and Mansour, S. L. (2011). Redundant and dosage sensitive requirements for Fgf3 and Fgf10 in cardiovascular development. Dev. Biol. 356, 383-397. doi: 10.1016/j.ydbio.2011.05.671
75. Vega-Hernández, M., Kovacs, A., De Langhe, S., and Ornitz, D. M. (2011). FGF10/FGFR2b signaling is essential for cardiac fibroblast development and growth of the myocardium. Development 138, 3331-3340. doi: 10.1242/dev.064410
76. Vincentz, J. W., McWhirter, J. R., Murre, C., Baldini, A., and Furuta, Y. (2005). Fgf15 is required for proper morphogenesis of the mouse cardiac outflow tract. Genesis 41, 192-201. doi: 10.1002/gene.20114
77. Virag, J. A., Rolle, M. L., Reece, J., Hardouin, S., Feigl, E. O., and Murry, C. E. (2007). Fibroblast growth factor-2 regulates myocardial infarct repair: effects on cell proliferation, scar contraction, and ventricular function. Am. J. Pathol. 171, 1431-1440. doi: 10.2353/ajpath.2007.070003
78. Wang, J., Sontag, D., and Cattini, P. A. (2015). Heart-specific expression of FGF-16 and a potential role in postnatal cardioprotection. Cytokine Growth Factor Rev. 26, 59-66. doi: 10.1016/j.cytogfr.2014.07.007
79. Wang, R., Yi, X., Li, X., and Jiang, X. (2015). Fibroblast growth factor-21 is positively associated with atrial fibrosis in atrial fibrillation patients with rheumatic heart disease. Int. J. Clin. Exp. Pathol. 8, 14901-14908
80. Wang, Z. G., Wang, Y., Huang, Y., Lu, Q., Zheng, L., Hu, D., et al. (2015). bFGF regulates autophagy and ubiquitinated protein accumulation induced by myocardial ischemia/reperfusion via the activation of the PI3K/Akt/mTOR pathway. Sci. Rep. 5:9287. doi: 10.1038/srep09287
81. Wang, Z., Wang, Y., Ye, J., Lu, X., Cheng, Y., Xiang, L., et al. (2015). bFGF attenuates endoplasmic reticulum stress and mitochondrial injury on myocardial ischaemia/reperfusion via activation of PI3K/Akt/ERK1/2 pathway. J. Cell. Mol. Med. 19, 595-607. doi: 10.1111/jcmm.12346
82. Watanabe, Y., Miyagawa-Tomita, S., Vincent, S. D., Kelly, R. G., Moon, A. M., and Buckingham, M. E. (2010). Role of mesodermal FGF8 and FGF10 overlaps in the development of the arterial pole of the heart and pharyngeal arch arteries. Circ. Res. 106, 495-503. doi: 10.1161/CIRCRESAHA.109.201665
83. Wilsbacher, L., and McNally, E. M. (2016). Genetics of cardiac developmental disorders: cardiomyocyte proliferation and growth and relevance to heart failure. Annu. Rev. Pathol. 11, 395-419. doi: 10.1146/annurev-pathol-012615-044336
84. Wohlfahrt, P., Melenovsky, V., Kotrc, M., Benes, J., Jabor, A., Franekova, J., et al. (2015). Association of fibroblast growth factor-23 levels and angiotensin-converting enzyme inhibition in chronic systolic heart failure. JACC Heart Fail. 3, 829-839. doi: 10.1016/j.jchf.2015.05.012
85. Wyatt, C. M., and Drüeke, T. B. (2016). Fibroblast growth factor receptor 4: the missing link between chronic kidney disease and FGF23-induced left ventricular hypertrophy? Kidney Int. 89, 7-9. doi: 10.1016/j.kint.2015.11.012
86. Yamakawa, H., Muraoka, N., Miyamoto, K., Sadahiro, T., Isomi, M., Haginiwa, S., et al. (2015). Fibroblast growth factors and vascular endothelial growth factor promote cardiac reprogramming under defined conditions. Stem Cell Reports 5, 1128-1142. doi: 10.1016/j.stemcr.2015.10.019
87. Yamasaki, S., Nabeshima, K., Sotomaru, Y., Taguchi, Y., Mukasa, H., Furue, M. K., et al. (2013). Long-term serial cultivation of mouse induced pluripotent stem cells in serum-free and feeder-free defined medium. Int. J. Dev. Biol. 57, 715-724. doi: 10.1387/ijdb.130173to
88. Yan, X., Chen, J., Zhang, C., Zhou, S., Zhang, Z., Chen, J., et al. (2015). FGF21 deletion exacerbates diabetic cardiomyopathy by aggravating cardiac lipid accumulation. J. Cell. Mol. Med. 19, 1557-1568. doi: 10.1111/jcmm.12530
89. Yu, C., Wang, F., Kan, M., Jin, C., Jones, R. B., Weinstein, M., et al. (2000). Elevated cholesterol metabolism and bile acid synthesis in mice lacking membrane tyrosine kinase receptor FGFR4. J. Biol. Chem. 275, 15482-15489. doi: 10.1074/jbc.275.20.15482
90. Yu, W., Huang, X., Tian, X., Zhang, H., He, L., Wang, Y., et al. (2016). GATA4 regulates Fgf16 to promote heart repair after injury. Development 143, 936-949. doi: 10.1242/dev.130971
91. Zhang, C., Huang, Z., Gu, J., Yan, X., Lu, X., Zhou, S., et al. (2015). Fibroblast growth factor 21 protects the heart from apoptosis in a diabetic mouse model via extracellular signal-regulated kinase 1/2-dependent signalling pathway. Diabetologia 58, 1937-1948. doi: 10.1007/s00125-015-3630-8
92. Zhang, F., Yu, L., Lin, X., Cheng, P., He, L., Li, X., et al. (2015). Roles of fibroblast growth factors 19 and 21 in metabolic regulation and chronic diseases. Mol. Endocrinol. 29, 1400-1413. doi: 10.1210/me.2015-1155
93. Zhang, J., Cheng, Y., Gu, J., Wang, S., Zhou, S., Wang, Y., et al. (2016). Fenofibrate increases cardiac autophagy via FGF21/SIRT1 and prevents fibrosis and inflammation in the hearts of Type 1 diabetic mice. Clin. Sci. 130, 625-641. doi: 10.1042/CS20150623
94. Zhang, R., Cao, P., Yang, Z., Wang, Z., Wu, J. L., Chen, Y., et al. (2015). Heparan sulfate biosynthesis enzyme, Ext1, contributes to outflow tract development of mouse heart via modulation of FGF signaling. PLoS ONE 10:e0136518. doi: 10.1371/journal.pone.0136518